Preliminary Analyses of QOL Data from the ABC-06 Clinical Trial

2022 Year in Review: Cholangiocarcinoma — January 4, 2023

Active symptom control (ASC) in conjunction with a modified L-folinic acid plus oxaliplatin plus 5-fluorouracil (mFOLFOX) regimen has emerged as a standard of care for advanced and metastatic biliary tract cancers (BTCs) following treatment with gemcitabine/cisplatin (GemCis). However, patient outcomes regarding quality of life (QOL) and value of health (V-He) have not been examined. This analysis of data collected as part of the randomized, phase 3, open-label, multicenter ABC-06 trial sought to determine the effect of ASC and mFOLFOX on QOL and V-He. Results were shared at the 2022 ESMO congress.

A total of 162 patients in the ABC-06 study who were diagnosed with advanced BTC that progressed following GemCis treatment were randomly assigned (1:1) to 1 of 2 treatment arms. Arm A received ASC alone, consisting primarily of supportive treatment, including biliary drainage, antibiotics, analgesia, steroids, antiemetics, and other palliative treatments to mitigate symptoms. Arm B received ASC interventions plus mFOLFOX. Patients’ perceptions of QOL and V-He were collected via questionnaires at baseline and every 12 weeks thereafter. Descriptive analyses of the QOL and V-He measures by study arm were reported, and patients who completed all or part of the QOL and V-He questionnaires were included in the interim analysis.

Data from 138 participating patients were eligible for analysis, with 65 in arm A (ASC alone) and 73 in arm B (ASC plus mFOLFOX). Baseline characteristics were well matched across both study arms. Patients receiving mFOLFOX plus ASC generally reported stable responses to questions assessing QOL, including metrics such as global health, physical health, and social function as well as symptoms of nausea, pain, and fatigue. Patients who received ASC alone reported worsening V-He perceptions and a decline in QOL for most indicators. These patients also reported an increase in nausea and pain. Additional analysis showed that adding mFOLFOX to ASC did not have a significant impact on the time to Global Health Scale deterioration.

Preliminary data from this study indicate that second-line treatment in patients with advanced BTCs with ASC plus mFOLFOX improved self-reported QOL and V-He scales versus ASC alone. In addition, patients receiving ASC plus mFOLFOX did not report an increase in nausea or pain from baseline to 4 months of follow-up. A fuller analysis of QOL and V-He data is ongoing.

Sources: Lamarca A, Palmer D, Wasan HS, et al. Quality of life (QoL) and value of health (V-He) in advanced biliary cancers (ABC) treated with second-line active-symptom-control (ASC) alone or ASC with oxaliplatin/5-FU chemotherapy (ASC+FOLFOX) in the randomised phase III, multi-centre, open-label ABC-06 trial. Ann Oncol. 2022;33(suppl 7):S564-S565.

Lamarca A, Palmer D, Wasan HS, et al. Quality of life (QoL) and value of health (V-He) in advanced biliary cancers (ABC) treated with second-line active-symptom-control (ASC) alone or ASC with oxaliplatin/5-FU chemotherapy (ASC+FOLFOX) in the randomised phase III, multi-centre, open-label ABC-06 trial. European Society for Medical Oncology Congress 2022. Abstract 54MO.

Related Items

KEYNOTE-966: Pembrolizumab Combined With GemCis Versus GemCis Alone in Patients With BTC
2023 Year in Review: Cholangiocarcinoma
In the KEYNOTE-966 study, pembrolizumab was added to gemcitabine/cisplatin to assess outcomes in patients with advanced biliary tract cancer.
Post-hoc Analysis of the ABC-01, -02, and -03 Trials in Patients With Advanced eCCA
2023 Year in Review: Cholangiocarcinoma
This post-hoc analysis of the ABC-01, -02, and -03 clinical trials provides reference survival data for patients with advanced extrahepatic cholangiocarcinoma treated with first-line gemcitabine/cisplatin chemotherapy.
Efficacy and Safety of Tinengotinib in Patients With Advanced Refractory/Relapsed CCA Who Previously Received an FGFR Inhibitor
2023 Year in Review: Cholangiocarcinoma
Investigators pooled data from 3 trials to evaluate tinengotinib in patients with advanced, refractory/relapsed cholangiocarcinoma who previously received an FGFR inhibitor.
KLF5 Inhibition Reduces Tumor Growth and Sensitizes to Chemotherapy-Induced Cell Death in Experimental Models of CCA
2023 Year in Review: Cholangiocarcinoma
Researchers evaluated KLF5 expression and its inhibition in cholangiocarcinoma using clustered regularly interspaced short palindromic repeats technology.
Phase 2 Trial of SHR-1316 Plus IBI310 in Patients With Advanced iCCA After Inadequate Response to First-Line Therapy
2023 Year in Review: Cholangiocarcinoma
In this ongoing phase 2 study, the efficacy of SHR-1316 plus IBI310 is being evaluated in patients with advanced intrahepatic cholangiocarcinoma after inadequate response to first-line therapy.
Examination of Patients With CCA Treated With Novel Targeted Therapies After Extended Molecular Profiling on Liquid Biopsies
2023 Year in Review: Cholangiocarcinoma
Dr Mahmood presented results from the largest multi-institutional review of efficacy outcomes following targeted agents in patients with cholangiocarcinoma.
Phase 2 Component of the BEER-BTC Study: Comparing Bevacizumab Plus Erlotinib Maintenance Versus Observation in Patients With Advanced BTC
2023 Year in Review: Cholangiocarcinoma
In the phase 2 component of the phase 2/3 BEER-BTC study, bevacizumab plus erlotinib improved outcomes in patients with advanced biliary tract cancers.
The DEBATE Trial: Neoadjuvant Durvalumab Plus GemCis Versus GemCis Alone for Patients With Localized BTC
2023 Year in Review: Cholangiocarcinoma
Researchers investigated the efficacy and safety of neoadjuvant durvalumab plus gemcitabine/cisplatin (GemCis) versus GemCis alone in patients with biliary tract cancer.
The Phase 2 ADJUBIL Study of Durvalumab Plus Tremelimumab With or Without Capecitabine in BTC
2023 Year in Review: Cholangiocarcinoma
In the ongoing phase 2 ADJUBIL study, the clinical activity of immunotherapies durvalumab and tremelimumab with or without capecitabine is being assessed in patients with resectable biliary tract cancer in the adjuvant setting.
Tucatinib and Trastuzumab in Patients With Previously Treated HER2-Positive Metastatic BTC: The SGNTUC-019 Study
2023 Year in Review: Cholangiocarcinoma
This phase 2 basket study investigated the combination of tucatinib and trastuzumab as second-line treatment for patients with HER2-positive biliary tract cancer.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: